Business Context and Reporting Period
This Form 6-K filing by Concord Medical Services Holdings Ltd (NYSE: CCM) is dated July 7, 2025. The report serves as a supplemental announcement regarding the 2024 Annual Report of its subsidiary, Concord Healthcare Group Co., Ltd. (Concord Healthcare), which is listed on the Hong Kong Stock Exchange (HKSE) under stock code 2453.HK. The primary purpose of this filing is to provide supplementary information specifically concerning proton therapy services.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document is a procedural announcement referencing a prior annual report rather than a standalone financial statement.
Material Changes
No material financial changes are detailed in this specific text. The filing notes the prior listing of Concord Healthcare's H shares on the HKSE on January 9, 2024, and directs investors to the HKSE website for transaction details.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future outlook, or specific risk factors. It strictly limits its scope to the disclosure of supplemental information regarding proton therapy services within the context of the 2024 Annual Report.
Investor Verification Checklist
- Verify the specific details of the proton therapy services in the full 2024 Annual Report of Concord Healthcare Group Co., Ltd.
- Review the HKSE website (www.hkexnews.hk) for transaction data related to Concord Healthcare (2453.HK).
- Confirm the financial impact of the proton therapy segment by cross-referencing the subsidiary's audited financial statements.